Roche - patience will be rewarded

Read 1 min

Roche: Not only a buy but also an undervalued stock according to the latest Publication of Vontobel Research. 
Having launched many drugs in recent years, Roche is set to grow at healthy rates in the coming years. Despite the failed trials in 2022, it should continue to do so after 2025, albeit at a slower pace.

This, in our view, could warrant a higher share price, but Roche has become a show-me story and will remain so until a major catalyst such as a pipeline success, an acquisition or a strategic change rekindles investor interest.

Due to the current low stock price and the promising future of Roche a Capped Outperformance Certificate could be an investment opportunity.

Would you like to learn more about Capped Outperformance Certificates
Reach out to our deritrade team today. We are here to guide you every step of the way, helping you achieve your financial goals with confidence and efficiency: